Real-world analysis shows reduced intraocular inflammation with aflibercept in pre-filled syringes, indicating potential benefits of this formulation.
In a real-world setting, aflibercept 8 mg was associated with a higher incidence of IOI than reported in pivotal trials, particularly when administered from vials. Conversion to the PFS markedly reduced the incidence, suggesting a formulation- or preparation-related effect. All cases were mild, anterior, and reversible under topical therapy without long-term visual impact.
No takes yet. Share an insight, caveat, or question.
Hoffmann et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: